SABCS Spin-Off | 06 - Vogel

Outside a protocol setting, carboplatin/docetaxel/trastuzumab followed by trastuzumab for a total duration of one year provides the best potential risk/benefit profile for elderly patients with ER-negative, PR-negative, HER2-positive, multiple node-positive breast cancer with a prior cardiac hist...